Gary Lyman, M.D., MPH, FACP, FRCP, professor of medicine (Medical Oncology), has been elected to the board of directors of the American Society of Clinical Oncology, the leading professional organization representing more than 30,000 oncologists and others who care for people with cancer.
Dr. Lyman will begin his four-year appointment in June 2012. As a member of the board, he will help set policies, oversee finances and influence the direction of the organization.
An expert in breast cancer, Lyman is director of the Comparative Effectiveness and Outcomes Research Program, a senior fellow at the Duke Center for Clinical Health Policy Research, and a member of the Duke Cancer Institute and Duke Center for Personalized Medicine. He serves as an advisor on new oncologic agents to the U.S. Food and Drug Administration, and also serves as editor-in-chief of the journal Cancer Investigation. An ASCO member since 1977, Lyman serves on the editorial boards of the Journal of Clinical Oncology and the Journal of Oncology Practice.
Lyman’s research interests include personalized management of early-stage breast cancer and supportive care of patients receiving chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Among his grants, Lyman is co-principal investigator on a National Cancer Institute study of comparative effectiveness of cancer pharmacogenomics and the validation of new genomic tools for guiding more personalized cancer treatments.
Additionally, Lyman leads efforts in evidence synthesis, clinical practice guidelines and health policy, conducting systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. He also conducts analyses of large population studies that examine clinical outcomes associated with current cancer patient management in a real world-setting, with a particular focus on cancer management in older cancer patients.
Lyman, who has published more than 350 peer-reviewed articles, has been at Duke since 2007. Previously, he held positions at the Moffitt Cancer Center and Research Institute, the University of South Florida, and the University of Rochester.
I am honored to be asked by the ASCO membership to serve in this capacity,” said Lyman. “I am committed to the society and its membership, as well as the patients that we serve, to work together to improve care, promote research and encourage policies that will eventually lead us to cure and prevent this disease.”
An expert in breast cancer, Lyman is director of the Comparative Effectiveness and Outcomes Research Program, a senior fellow at the Duke Center for Clinical Health Policy Research, and a member of the Duke Cancer Institute and Duke Center for Personalized Medicine. He serves as an advisor on new oncologic agents to the U.S. Food and Drug Administration, and also serves as editor-in-chief of the journal Cancer Investigation. An ASCO member since 1977, Lyman serves on the editorial boards of the Journal of Clinical Oncology and the Journal of Oncology Practice.
Lyman’s research interests include personalized management of early-stage breast cancer and supportive care of patients receiving chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Among his grants, Lyman is co-principal investigator on a National Cancer Institute study of comparative effectiveness of cancer pharmacogenomics and the validation of new genomic tools for guiding more personalized cancer treatments.
Additionally, Lyman leads efforts in evidence synthesis, clinical practice guidelines and health policy, conducting systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. He also conducts analyses of large population studies that examine clinical outcomes associated with current cancer patient management in a real world-setting, with a particular focus on cancer management in older cancer patients.
Lyman, who has published more than 350 peer-reviewed articles, has been at Duke since 2007. Previously, he held positions at the Moffitt Cancer Center and Research Institute, the University of South Florida, and the University of Rochester.